 Plasma exchange chronic progressive multiple sclerosis long-term study Plasma exchange PE previous double-blind study significant additional benefit year patients chronic progressive multiple sclerosis CPMS immunosuppressive drug therapy ISDT Efficacy extended term indications retreatment long-term toxicity analysis number patients past years patients CPMS PE low-dose ISDT center Improvement Kurtzke Disability Status Scale steps post-therapy follow-up significant comparison pre-PE disability status Clinical improvement majority patients follow-up Major life-threatening complications attributable therapy